Videos

Triplet and Quadruplet Therapy Options for Patients With Transplant-Eligible NDMM

Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Future Directions in mHSPC Management: An Evolving Treatment Landscape

An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

Alan H. Bryce, MD;Benjamin Lowentritt, MD;Daniel P. Petrylak, MD;Tian Zhang MD, MHS

Patient Profile 1: A 61-Year-Old with Transplant-Eligible Newly Diagnosed MM

Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma

A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.

C. Ola Landgren, MD, PhD

Transplant Eligibility in Patients With NDMM

C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

The Future of Immunotherapies in Advanced/Recurrent Endometrial Cancer Treatment

Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.

Robert L. Coleman, MD, FACOG, FACS;Ramez Eskander, MD;Sharyn Lewin, MD, FACS

Unmet Needs in Diffuse Large B-Cell Lymphoma

Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.

Andre H. Goy, MD, an expert on B-cell malignancies

Andre H. Goy, MD;Andrew Ip, MD

Efficacy of Immunotherapies for dMMR or MMRp Advanced/Recurrent Endometrial Cancer

Andre H. Goy, MD, and Andrew Ip, MD, offer closing remarks on unmet needs in the treatment of diffuse large B-cell lymphoma.

Robert L. Coleman, MD, FACOG, FACS;Ramez Eskander, MD;Sharyn Lewin, MD, FACS

DLBCL: Treatment Considerations in the Second Line

The panel discusses their opinions on the use of immunotherapy in different populations of women with advanced/recurrent endometrial cancer.

Andrew Ip, MD, an expert on B-cell malignancies

Andre H. Goy, MD;Andrew Ip, MD

Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)

Experts on diffuse large B-cell lymphoma discuss the factors that inform their treatment choices in the second line.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

The Future of Immunotherapy is ‘Bright’ in Multiple Myeloma

Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.

C. Ola Landgren, MD, PhD

Selecting Patients with MM for Teclistamab and Optimal Sequencing

C. Ola Landgren, MD, PhD, speaks about transplant eligibility, as well as new therapies and minimal residual disease negativity, in the multiple myeloma space.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment

The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Patient Case 3: Development of CRS on a Non-BCMA Targeted Bispecific Antibody

Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.

Ajai Chari, MD;Annel Urena, RN;Kiah Purcell, NP;Robert Mancini, PharmD, BCOP

Managing Neurotoxicity Associated with Bispecifics in MM

Centering discussion on the third patient case of multiple myeloma, key opinion leaders consider the development of CRS on non-BCMA targeted bispecific antibody therapy.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Case 2: A 57-Year-Old With R/R MM Treated with Bispecifics and Develops Neuropathy

A comprehensive discussion on managing neurotoxicity associated with bispecific antibodies in multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma

A panel of experts on multiple myeloma offer insights on the case of a 57-year-old with relapsed/refractory MM treated with an FcRH5 bispecific antibody who develops peripheral neuropathy.

Ajai Chari, MD;Kiah Purcell, AGPCNP-B;Annel Urena, RN, BSN;Robert Mancini, PharmD, BCOP

Management of ICANS Associated with Bispecific Antibodies in MM

Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.

Ajai Chari, MD;Annel Urena, RN;Kiah Purcell, NP;Robert Mancini, PharmD, BCOP

Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab

A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Multiple Myeloma: Use of Bispecifics in Challenging Patient Populations

Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.

Amrita Y. Krishnan, MD;Sandy Wong, MD;Philippe Moreau, MD;Alfred Garfall, MD;Joshua Richter, MD

May 23rd 2023

Before closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.

Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC

Toni K. Choueiri, MD;Rohit Gosain, MD

A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions

Toni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.

Toni K. Choueiri, MD;Rohit Gosain, MD

Treatment Paradigm for Patients With Transplant Ineligible NDMM

A brief overview of post-hoc data from the CheckMate 9ER trial examining baseline characteristics and time to subsequent therapy in patients who received at least two years of nivolumab treatment, followed by study conclusions.

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression

Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.

Cathy Eng, MD;Suneel D. Kamath, MD;Michael Foote, MD;Arvind Dasari, MD, MS;Aparna Raj Parikh, MD, MS